Evonik announced the establishment of a Scientific Advisory Board that will help the Company expand its position as a leading global partner to pharmaceutical companies in the development and production of complex parenteral drug products.
Evonik’s business line Health Care, which forms part of the Nutrition and Care segment of the Company, is a global CDMO leader for advanced drug delivery. For over four decades, its portfolio of excipients, formulation and process technologies and manufacturing services has helped pharmaceutical companies transform their APIs into high-performance medicines.
Evonik has a clear mandate to expand its presence within the growth engine, Health & Care. Accordingly, the Company is fully committed to supporting customers in the development and production of complex parenteral drug products for use within fast-growing markets including gene and cell-based therapies. Evonik will leverage the expertise of the new Scientific Advisory Board to help ensure its portfolio of technologies and related services continue to effectively deliver small molecules, peptides, proteins and mRNA across a range of fast-growing therapeutic areas such as rare and degenerative diseases, oncology, ophthalmology, and vaccines.
The three founding members of the Scientific Advisory Board are Professor Daan Crommelin, professor emeritus at the Department of Pharmaceutics at Utrecht University in the Netherlands; Professor Pieter Cullis, Scientific Director and CEO of the NanoMedicines Innovation Network (NMIN) at the University of British Columbia in Canada; and Dr. Mark Tracy, Founder and President of Tracy BioConsulting, LLC. Each advisor has more than 20 years of expertise in the development of polymeric and lipid nanoparticle (LNP)-based drug delivery technologies, and complex parenteral drug products.
Dr. Stefan Randl, Vice-President of Innovation Management at the Health Care business line of Evonik, said “Evonik is dedicated to building long-term collaborations with pharmaceutical industry partners that share our commitment to addressing emerging market needs in the formulation development and production of complex parenteral drug products. The appointment of these pre-eminent thought leaders to our new Scientific Advisory Board will help to ensure that Evonik continues to remain a preferred CDMO partner for advanced drug delivery.”
